Literature DB >> 7772432

Human cytochrome P450 mono-oxygenase system is suppressed by propofol.

T L Chen1, T H Ueng, S H Chen, P H Lee, S Z Fan, C C Liu.   

Abstract

We have studied the effect of propofol on the cytochrome P450-dependent mono-oxygenase system in human liver microsomes by assaying mono-oxygenase activities toward specific cytochrome P450 isoform test substrates, aniline, 7-ethoxycoumarin, benzphetamine and benzo(a) pyrene. Propofol inhibited benzo(a)pyrene hydroxylation to a greater extent than the oxidative metabolism of the other test substrates, even at 0.05 mmol litre-1. The degrees of inhibition of benzphetamine N-demethylation and 7-ethoxy-coumarin O-de-ethylation were similar, while aniline hydroxylation was least affected by propofol. Spectral analysis showed that propofol competed with carbon monoxide for binding to the haem moiety of haemoprotein in the P450 enzyme. The variable inhibition observed may be caused by the differential binding of propofol to P450 isoforms. Propofol 0.05-1.0 mmol litre-1 exhibited a concentration-dependent inhibitory effect on human cytochrome P450 2E1, 2B1 and 1A1. These inhibitory actions of propofol on human liver microsomal enzymes in vitro suggest that potential drug interactions may exist between propofol and other drugs administered clinically.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772432     DOI: 10.1093/bja/74.5.558

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Use of propofol to control refractory involuntary movements.

Authors:  David V Lardizabal; Vivek Sabharwal; Ali Jahan; Samay Jain; Christopher Snyder; Marc J Popovich; Michael DeGeorgia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

2.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 3.  Pain management in the critically ill child.

Authors:  M Yaster; D G Nichols
Journal:  Indian J Pediatr       Date:  2001-08       Impact factor: 1.967

4.  Effect of propofol on ropivacaine metabolism in human liver microsomes.

Authors:  Yoshiko Osaka; Shinichi Inomata; Einosuke Tanaka; Takako Nakamura; Katsuya Honda; Masayuki Miyabe; Hidenori Toyooka; Makoto Tanaka
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

5.  Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.

Authors:  Einosuke Tanaka; Yui Takano; Shinichi Inomata; Hidenori Toyooka; Katsuya Honda
Journal:  Eur J Clin Pharmacol       Date:  2004-09-04       Impact factor: 2.953

Review 6.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 7.  Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.